acl's phase 2 was open label, their phase 3 wasn't.
neu's phase 2 was double blinded with a patient group that was very unlikely to be effected by the placebo effect.
In neu's phase 2 the placebo patients showed little alteration. The lower dose showed improvement and the higher dose showed good improvement. Just what one want's to see.
There's still risk, but I agree that acl and neu are world's apart.
A possibility worth worth contemplating, page-11
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.17 |
Change
-0.970(4.38%) |
Mkt cap ! $2.716B | |||
| Open | High | Low | Value | Volume |
| $22.06 | $22.11 | $21.07 | $3.713M | 172.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21 | $21.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.18 | 65 | 4 |
View Market Depth
| Last trade - 11.58am 18/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |